Healthcare Industry News: HemoSense
News Release - February 9, 2007
HemoSense Names Conan Li to VP of Research & DevelopmentSAN JOSE, Calif.--(HSMN NewsFeed)--HemoSense, Inc. (AMEX:HEM ) today announced that Conan Li, Ph.D., 55, has joined the Company as vice president, research and development. Dr. Li replaces Mags McInerney, Ph.D., who resigned in November 2006 to pursue other business opportunities.
"Conan brings to HemoSense more than 25 years of impressive product development and leadership experience at top-tier diagnostic companies, as well as a distinguished scientific background," said Jim Merselis, president and CEO of HemoSense. "Throughout his career Conan has played instrumental roles in the diagnostics space including his contributions through senior management positions, committees and boards and at various key companies and institutions including Roche, Quest Diagnostics and Abbott Laboratories. As we look to enhance our current product offering and broaden our technology platform, we believe Conan's expertise will further augment our R&D capabilities."
Most recently Dr. Li was R&D manager of molecular diagnostics and a member of the Life Sciences R&D Council at Agilent Technologies Inc., where he led a multidisciplinary team to complete novel diagnostic assays and instituted the automation of a manual assay procedure. Prior to that, he led the development of in vitro test platforms as the senior vice president and chief technology officer of VaxDesign Corporation, a privately held biotechnology company. He was also the director of the Advanced Technology Group at Quest Diagnostics Nichols Institute, where his responsibilities included directing new technology R&D, developing strategic alliances and new business development. During his career Dr. Li has also served as vice president of product development at Cellomics, Inc., a biotechnology instrumentation company; vice president of science and research at Xylum Corporation, a start up medical device company; and senior biochemist of the Diagnostics Division at Abbott Laboratories where he was responsible for the development of several key patents.
Dr. Li has also served on numerous committees and boards including as the co-chairman of the Biorheology Scientific and Standardization Committee of the International Society of Hemostasis and Thrombosis and as an advisor to the National Committee on Clinical Laboratory Standards Subcommittee of Point-of-Care Coagulation Testing.
Dr. Li holds an MBA from Cornell University, a Ph.D. in biophysics from Harvard University and a bachelor's of science degree in physics from the Massachusetts Institute of Technology.
HemoSense is a point-of-care diagnostic healthcare company that develops, manufactures and markets easy-to-use, handheld blood coagulation systems for monitoring patients taking warfarin. The HemoSense INRatio® system, used by healthcare professionals and patients themselves, consists of a small monitor and disposable test strips. It provides accurate and convenient measurement of blood clotting time, or PT/INR values. Routine measurements of PT/INR are necessary for the safe and effective management of the patient's warfarin dosing. INRatio is sold in the United States and internationally. For more information, visit www.HemoSense.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's ability to enhance its current product offering and broaden its technology platform may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties which may cause the actual results to differ materially from the statements contained herein. Further information on the Company's business and risk factors are detailed in its filings with the Securities and Exchange Commission, including its 2006 Form 10-K filed on December 27, 2006. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
HemoSense® and INRatio® are registered trademarks of HemoSense, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.